EUVIMEDSkopri EUVIMED
Crossref

Synergistic Antitumor Effects and Reduced Systemic Toxicity of Berberine Chloride Combined With Cisplatin in a Female BALB/c Mouse Xenograft Model

Abir Salek iD, Haifa Messai, Mouna Selmi iD, Aida Lahmer, Maram Selmi, Fedia Jaber iD, Refka Hassine iD, Sihem Safta, Asma Omezzine, Leila Chekir-Ghedira iD

Cell Biology International · 2026-10 · 50 (10)

DOI: 10.1002/cbin.70211 ↗

At a glance

Journal article in Cell Biology International, published online on 2026-09-28. Written by Abir Salek and 9 co-authors. Institution: Research Laboratory of Bioactive Natural Products and Biotechnology, Faculty of Dental Medicine, University of Monastir, Monastir, Tunisia. Major MEDLINE topics: Berberine, Cisplatin, Antineoplastic Agents. 43 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Breast cancer, especially triple‐negative breast cancer (TNBC), remains a significant clinical challenge due to limited treatment options, chemoresistance, and the toxic side effects of standard chemotherapy. Cisplatin (Cis) is commonly used but faces limitations from resistance and dose‐related toxicity. Berberine chloride (BRB), a natural alkaloid derived from Berberis vulgaris, shows promising anticancer effects. This study examined the antitumor activity and chemosensitizing potential of BRB combined with Cis. We initially examined the effects of BRB and Cis on murine 4T1 breast cancer cells. The results showed that both treatments inhibited cell viability, with IC50 values around 10 µM for BRB and 2.5 µM for Cis. Subsequently, we tested the synergistic effects using the Chou–Talalay method, which indicated that most of the 16 drug combinations exhibited synergy (CI < 1). The most effective combination (IC 50 /8) had a CI of 0.12 and a Fa of 0.8, greatly reducing cell viability compared to individual treatments. The combined BRB and Cis therapy was then tested in a BALB/c mouse xenograft model via intraperitoneal injection. Cis alone at 1 mg/kg weekly lowered tumor growth by 43.13% but caused notable systemic toxicity, including body weight loss and kidney and liver damage. BRB alone at 10 mg/kg every 2 days resulted in greater tumor suppression (61.17%) with fewer side effects. The BRB/Cis combo achieved the highest tumor growth inhibition (87.05%) and markedly reduced Cis‐related toxicity, evidenced by weight recovery and improved kidney and liver biochemical markers. These results indicate that BRB enhances cisplatin's antitumor effects while decreasing systemic toxicity, positioning BRB as a promising chemosensitizer for TNBC therapy.

Subjects

MeSH terms (MEDLINE)

BerberineCisplatinAntineoplastic AgentsAnimalsFemaleMice, Inbred BALB CDrug SynergismCell Line, TumorMiceXenograft Model Antitumor AssaysCell SurvivalHumansTriple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy Protocols

Author keywords

berberine chloride (BRB)breast cancerchemosensitivitycisplatin (Cis)drug synergysystemic toxicityxenograft model

Substances

BerberineCisplatinAntineoplastic Agents

Authors and institutions

  • Research Laboratory of Bioactive Natural Products and Biotechnology, Faculty of Dental Medicine, University of Monastir, Monastir, Tunisia.
  • Research Laboratory of Biochemistry, University Hospital (CHU) Sahloul in Sousse and the Faculty of Pharmacy at the University of Monastir, Monastir, Tunisia.
  • ABCDF Laboratory, Faculty of Dental Medicine, University of Monastir, Monastir, Tunisia.

ORCID profiles: Abir Salek, Mouna Selmi, Fedia Jaber, Refka Hassine, Leila Chekir-Ghedira

Cite

APA

Salek, A., Messai, H., Selmi, M., Lahmer, A., Selmi, M., Jaber, F., Hassine, R., Safta, S., Omezzine, A., & Chekir-Ghedira, L. (2026). Synergistic Antitumor Effects and Reduced Systemic Toxicity of Berberine Chloride Combined With Cisplatin in a Female BALB/c Mouse Xenograft Model. Cell Biology International, 50(10). https://doi.org/10.1002/cbin.70211

Vancouver

Salek A, Messai H, Selmi M, Lahmer A, Selmi M, Jaber F, et al. Synergistic Antitumor Effects and Reduced Systemic Toxicity of Berberine Chloride Combined With Cisplatin in a Female BALB/c Mouse Xenograft Model. Cell Biology International. 2026;50(10). doi:10.1002/cbin.70211

BibTeX
@article{Salek2026,
  author = {Salek, Abir and Messai, Haifa and Selmi, Mouna and Lahmer, Aida and Selmi, Maram and Jaber, Fedia and Hassine, Refka and Safta, Sihem and Omezzine, Asma and Chekir-Ghedira, Leila},
  title = {Synergistic Antitumor Effects and Reduced Systemic Toxicity of Berberine Chloride Combined With Cisplatin in a Female BALB/c Mouse Xenograft Model},
  journal = {Cell Biology International},
  year = {2026},
  volume = {50},
  number = {10},
  doi = {10.1002/cbin.70211}
}
Start for free →